Correlation Analysis of Target Selectivity and Side Effects of FDA‐Approved Kinase Inhibitors**

Kinase inhibitors (KIs) represent a popular class of therapeutic agents and chemical probes but most them tend to be polypharmacological. Receptor non-receptor Tyrosine KIs can target more than 100 kinases simultaneously compare other KIs. We here analyze the molecular targets 41 U.S. Food Drug Administration (FDA)-approved chose 18 drugs (Tyrosine KIs) sought out evaluate their selectivity profile engagement with number in vivo at clinically relevant doses. also wanted see whether there prevails any correlation between reported side effects for specific chosen as test cases. To explore all clinical KIs, we considered free (unbound) maximum serum concentration (Cmax) each KI only which cognate affinities lie within Cmax values, thereby allowing plausible interaction retrieved those that is FDA adverse event reporting system. illustrate how analysis target-side effect give new insight into off on increasing toxicity These analyses could aid our understanding structural-activity relationship